Lab-grown, 3D extracellular matrix particles improve cardiac function and morphology in myocardial ischemia

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Cardiovascular Research

Background:

• Traditional animal-derived extracellular matrix (ECM) therapies for myocardial ischemia face challenges with immune reactions and extraction.
• Lab-grown human ECM offers a potential solution to mitigate variability and immunogenicity while preserving ECM architecture.

Purpose of the Study:

• To develop and evaluate novel 3-D acellular ECM particles derived from human mesenchymal stem cells (MSCs).
• To assess the therapeutic efficacy of intramyocardial injection of these ECM particles in a murine model of myocardial infarction (MI).

Main Methods:

• Developed lab-grown, 3-D human acellular ECM particles from MSCs.
• Administered intramyocardial injections of ECM particles or saline into mice post-MI.
• Evaluated cardiac function, infarct size, capillary density, and immunogenic response via echocardiography and molecular assays.
• Performed proteomic analysis using LC-MS/MS to identify molecular changes.

Main Results:

• ECM treatment significantly reduced infarct size and increased capillary density in the ischemic myocardium.
• Fractional shortening (cardiac function) was significantly improved in ECM-treated mice compared to controls.
• No significant differences in immunogenic markers (TNFα, IL6, CD86, CD163) were observed.
• Proteomic analysis revealed ECM-induced upregulation of proteins involved in cardiomyocyte contractility and fatty acid metabolism.

Conclusions:

• Novel 3-D human ECM particles promote recovery of ischemic myocardium by modulating protein networks related to contractility and metabolism.
• These ECM particles represent a promising, potentially non-surgical therapeutic strategy for myocardial infarction.
• Further studies in large animal models are warranted to confirm efficacy.